Erlotinib intermediates manufacturer
MF:C22H24N2O7S
Place of Origin: China (Mainland)
Type:ankylosing spondylitis, Behcet's disease, and rheumatoid arthritis.
Grade Standard:Medicine Grade
Purity:99%min
Product Name:Apremilast
Appearance:White Crystalline Powder
Grade:Medicine Grade
Name:Apremilast
Assay:HPLC 99%
Shelf Life:2 Years
Color:White Color
Place Of Origin: China(Mainland)
COA:Available
Supply Ability
1000 Kilogram/Kilograms per Month 1 Tons Per Month
Packaging & Delivery
Packaging Details
0.01kg/bag 25kg/drum
According to your needs
Port :Any port in China
Lead Time :Within 10 Days after the payment
Apremilast was approved by the USFDA in March 2014 for treatment of adults with active psoriatic arthritis. Apremilast is the first oral agent that is FDA-approved for the treatment of psoriatic arthritis and offers the convenience of oral dosing compared to treatment with biopharmaceuticals. In September 2014, the USFDA approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis.It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcet's disease, and rheumatoid arthritis.
|
Product Name: |
Apremilast |
MF: |
C22H24N2O7S |
|
CAS NO.: |
608141-41-9 |
Method: |
HPLC |
|
Purity: |
99% |
Origin: |
China |
|
Items |
Specifications |
Results |
|
Appearance |
Off-white to white powder |
Off-white powder |
|
Assay(HPLC) |
≥99% |
99.87% |
|
Related Substances |
Any single unknown impurity≤0.1% Total impurities:≤0.5% |
0.09% 0.13% |
|
Enantiomer |
<0.5% |
0.12% |
|
Loss on drying |
Not more than 0.5% |
0.03% |
|
Melting Point |
154~158℃ |
155.6~156.7℃ |
|
Residue on ignition |
Not more than 0.5% |
0.01% |
|
Residual solvents |
Methanol <3000ppm Ethanol <5000ppm THF<720ppm Acetonitrile<410ppm Acetone <5000ppm Dichloromethane <600ppm |
560ppm N.D. N.D. 66ppm 800ppm N.D. |
|
Conclusion |
Conform with specification |
|
Storage |
Store in sealed containers at cool & dry place. |
|
|
Protect from light, moisture and pest infestation. |
|
Shelf Life |
2 years when properly stored |
Function
Apremilast is a new class of oral small-molecule inhibitors of phosphodiesterase 4 (PDE4) enzyme. When PDE4 is inhibited in the immune cell, it causes a rise in the level of the cell's inner cyclic adenosine acid (cAMP), which regulates the inflammatory mediators. Current clinical data indicate that apremilast is an effective and tolerable choice for treating psoriasis and PsA in adults.
Application
Apremilast is an orally available small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast specifically inhibits PDE4 and inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells. It has anti-inflammatory activity.
